Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | HTR2B | P41595 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2261151 | 0.91 | HTR2A (0.47) | HTR2AHTR2CHTR2BMAPTCYP3A4 | |
| SCHEMBL18840447 | 0.86 | HTR2C (0.55) | HTR2AHTR2CHTR2BMAPTCYP3A4 | |
| SCHEMBL4612611 | 0.80 | TDP1 (0.31) | — | |
| SCHEMBL4612593 | 0.80 | — | — | |
| SCHEMBL18840444 | 0.78 | NR1H2 (0.43) | MAPTCYP3A4NR1H2NR1H3KDM4E | |
| SCHEMBL2262585 | 0.78 | NR1H2 (0.32) | NR1H2NR1H3 | |
| SCHEMBL12892693 | 0.77 | NR1H2 (0.41) | HTR2AHTR2CHTR2BNR1H2NR1H3 | |
| SCHEMBL19912596 | 0.77 | — | — | |
| SCHEMBL12390316 | 0.76 | NR1H2 (0.46) | HTR2AHTR2CHTR2BMAPTCYP3A4 | |
| SCHEMBL4612437 | 0.74 | KDM1A (0.33) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633762-B1 | Paracyclophanes | JOHNSON MATTHEY PLC (GB) | 2008-10-29 | — | — | EP | disclosed |
| US-7256302-B2 | Catalyst ligand with groups on one or both of the benzene rings in a paracyclophane structure; high activity and selectivity for asymmetric reactions, facilitate chiral resolution | JOHNSON MATTHEY PLC (GB) | 2007-08-14 | — | — | US | disclosed |
| US-7256302-B2 | Catalyst ligand with groups on one or both of the benzene rings in a paracyclophane structure; high activity and selectivity for asymmetric reactions, facilitate chiral resolution | JOHNSON MATTHEY PLC (GB) | 2007-08-14 | — | — | US | disclosed |
| US-20060229473-A1 | Catalyst ligand with groups on one or both of the benzene rings in a paracyclophane structure; high activity and selectivity for asymmetric reactions, facilitate chiral resolution | JOHNSON MATTHEY PLC (GB) | 2006-10-12 | — | — | US | disclosed |
| EP-1633762-A1 | LIGANDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004111065-A1 | LIGANDS | JOHNSON MATTHEY PLC (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229473-A1 | Catalyst ligand with groups on one or both of the benzene rings in a paracyclophane structure; high activity and selectivity for asymmetric reactions, facilitate chiral resolution | C1S, CCR1, CYC1 | HTR2A 3056/4885HTR2C 1421/4885HTR2B 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.